AI may cut drug development time, says Biocon's Kiran Mazumdar-Shaw
Artificial Intelligence (AI) has the potential to drastically cut the time required to take a drug molecule from the lab to patients, compressing the current five-to-seven-year timeline into just one or two years, Kiran Mazumdar-Shaw of Biocon said on Tuesday. Speaking on the role of AI in life sciences, Shaw, the Executive Chairperson, Biocon Ltd, noted that accelerating this journey from lab to clinic will unlock major opportunities in precision and personalised medicine. "Ultimately the proc…


